Volume 3.10 | Mar 17

Human Immunology News 3.10 March 17, 2015
Human Immunology News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Like Us on Facebook  HIN on Twitter
 
TOP STORY
Tetanus Shot Improves Patient Survival with Brain Tumor Immunotherapy
An innovative approach using a tetanus booster to prime the immune system enhances the effect of a vaccine therapy for lethal brain tumors, dramatically improving patient survival. [Press release from Duke University discussing online prepublication in Nature] Press Release | Abstract
March Magnet Maddness: Free EasySep™ Magnet with Purchase of Cell Isolation Reagents
 
PUBLICATIONS (Ranked by impact factor of the journal)
The Genetic Architecture of the Human Immune System: A Bioresource for Autoimmunity and Disease Pathogenesis
Investigators undertook a comprehensive immunophenotyping approach, analyzing 78,000 immune traits in 669 female twins. They found multiple associations with canonical traits of all major immune cell subsets and uncovered insights into genetic control for regulatory T cells. [Cell]
Abstract | Graphical Abstract | Press Release

Mutational Landscape Determines Sensitivity to PD-1 Blockade in Non-Small Cell Lung Cancer
Scientists used whole-exome sequencing of non-small cell lung cancers treated with pembrolizumab, an antibody targeting programmed cell death-1 (PD-1). In two independent cohorts, higher nonsynonymous mutation burden in tumors associated with improved objective response, durable clinical benefit, and progression-free survival. [Science] Abstract | Press Release | Video

Anti-IL-23A mAb BI 655066 for Treatment of Moderate-to-Severe Psoriasis: Safety, Efficacy, Pharmacokinetics, and Biomarker Results of a Single-Rising-Dose, Randomized, Double-Blind, Placebo-Controlled Trial
BI 655066 is a fully human IgG1 mAb specific for the IL-23 p19 subunit. This first-in-human proof-of-concept study evaluated the clinical and biological effects of BI 655066 in patients with moderate-to-severe plaque psoriasis. [J Allergy Clin Immunol] Abstract | Press Release

The ​Interferon-Related Developmental Regulator 1 Is Used by Human Papillomavirus to Suppress NFκB Activation
Using non-infected and freshly established or persistent hrHPV-infected keratinocytes researchers showed that high-risk human papillomavirus impaired the acetylation of NFκB/​RelA K310 in keratinocytes. As a consequence, keratinocytes display a decreased pro-inflammatory cytokine production and immune cell attraction in response to stimuli of the innate or adaptive immune pathways. [Nat Commun] Full Article

Reprogramming of Primary Human Philadelphia Chromosome-Positive B Cell Acute Lymphoblastic Leukemia Cells into Nonleukemic Macrophages
Investigators found that primary human BCR-ABL1+ precursor B-cell acute lymphoblastic leukemia cells could be induced to reprogram into macrophage-like cells by exposure to myeloid differentiation-promoting cytokines in vitro or by transient expression of the myeloid transcription factor C/EBPα or PU.1. [Proc Natl Acad Sci USA] Abstract | Press Release

Tim-3 Protects Decidual Stromal Cells from Toll-Like Receptor-Mediated Apoptosis and Inflammatory Reactions and Promotes Th2 Bias at the Maternal-Fetal Interface
Researchers demonstrated significantly lowered expression of T-cell immunoglobulin and mucin domain 3 (Tim-3) in miscarried decidual stromal cells, indicating that Tim-3 might play important roles in maintaining successful pregnancies. [Sci Rep] Full Article

Heterozygosity for the Common Perforin Mutation, p.A91V, Impairs the Cytotoxicity of Primary Natural Killer Cells from Healthy Individuals
Researchers investigated the function of p.A91V on a wild-type perforin background. They demonstrated that the p.A91V mutation results in protein misfolding and an appreciable reduction in natural killer cell cytotoxicity in healthy carriers of p.A91V. [Immunol Cell Biol] Abstract

A New Effect of IL-4 on Human γδ T Cells: Promoting Regulatory Vδ1 T Cells via IL-10 Production and Inhibiting Function of Vδ2 T Cells
Scientists investigated the effects of interleukin 4 (IL-4) on the activation and proliferation of γδ T cells and the balance between variable delta 1 (Vδ1) and Vδ2 T cells in humans. The results showed that IL-4 inhibited the activation of γδ T cells in the presence of γδ T-cell receptor stimulation in a STAT6-dependent manner. [Cell Mol Immunol] Abstract

Clinical Testing of a Dendritic Cell Targeted Therapeutic Vaccine in Patients with Chronic Hepatitis C Virus Infection
Due to the central role that dendritic cells (DC) play in the activation of T-cell responses, scientists aimed to carry out a therapeutic vaccination clinical trial in hepatitis C virus patients using DC. [Mol Ther Methods Clin Dev] Full Article

Subscribe to our sister publications:
Immunology of Infectious Disease News and Immune Regulation News
!

Request a Sample: 8 minutes to highly purified immune cells with EasySep™.
 
REVIEWS
The Interaction of Anticancer Therapies with Tumor-Associated Macrophages
A better understanding of the interaction of anticancer therapies with innate immunity, and tumor-associated macrophages in particular, may pave the way to better patient selection and innovative combinations of conventional approaches with immunotherapy. [J Exp Med] Abstract

Visit our reviews page to see a complete list of reviews in the human immunology research field.
 
SCIENCE NEWS
Advaxis Presents Preliminary Data from a Phase I/II Trial of ADXS-HPV in HPV-Associated Anal Cancer in Combination with Chemoradiation Showing Complete Response and No Recurrences to Date in All Treated Patients
The preliminary data show that the investigational immunotherapy was well tolerated by treated patients, and all treatment-related toxicities were within 24 hours of dosing, the most frequent of which include chills/rigors, fever and nausea. [Press Release from Advaxis, Inc. discussing research presented at the International Anal Neoplasia Society (IANS) Scientific Meeting 2015, Atlanta] Press Release

Inflammation in the Mouth and Joints in Rheumatoid Arthritis
Sheila Arvikar, Massachusetts General Hospital, presented a study titled, “Inflammation in the Mouth and Joints in Rheumatoid Arthritis.” [Press release from the International Association for Dental Research (IADR) discussing research presented at the 93rd General Session and Exhibition of the IADR, Boston] Press Release

Immunicum’s Chief Scientific Officer Presented the Technology behind the Cancer Vaccine INTUVAX
Immunicum AB announced that the company’s Chief Scientific Officer, Dr. Alex Karlsson-Parra, has presented the technology behind the cancer vaccine INTUVAX. [Press release from Immunicum AB discussing research presented at the Symposium on Breakthroughs in Clinical & Translational Immunology, Stockholm] Press Release

From our sponsor:
View immunology lectures, protocols and other resources on the
Human Immunology Portal.
 
INDUSTRY NEWS
The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology
The Bill & Melinda Gates Foundation and CureVac announced that the foundation has made a commitment to invest $52 million in CureVac, a leading clinical-stage biopharmaceutical company specializing in mRNA-based vaccine technologies. [The Bill & Melinda Gates Foundation] Press Release

Cell Medica Collaborates with Cell Therapy Catapult to Help Bring Its New Treatment to NHS
The Cell Therapy Catapult and Cell Medica announced a collaboration to accelerate NHS adoption of Cell Medica’s Cytovir™ CMV. Cytovir™ CMV is an individualized immune cell therapy that involves the infusion of immune cells from a donor into an immunosuppressed patient, in order to reconstitute their immunity to cytomegalovirus (CMV). [Cell Therapy Catapult] Press Release

New Immunotherapy Drug ‘Fast-Tracked’ for Melanoma Patients
A new immunotherapy drug, pembrolizumab, has become the first treatment ‘fast-tracked’ for NHS patients with advanced melanoma. Clinical trials have shown that it has the potential to ease symptoms and extend survival. [Cancer Research UK] Press Release

VAXIL Receives EU Orphan Drug Designation for ImMucin for the Treatment of Multiple Myeloma
Vaxil Bio reports that its lead drug candidate, ImMucin has received orphan drug designation from the European Medicines Agency of the European Commission for the treatment of multiple myeloma. [Vaxil BioTherapeutics Ltd.] Press Release

MacroGenics Initiates Phase I Study of MGD010 for the Treatment of Autoimmune Disorders
MacroGenics, Inc. announced the initiation of a Phase I study with MGD010, its first dual-affinity re-targeting (DART®) molecule being developed for patients with autoimmune disorders. [MacroGenics, Inc.] Press Release
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW The 2nd Cancer Vaccine Institute International Symposium on Immunotherapy
May 15-16, 2015
London, United Kingdom

NEW International Workshop on Artificial Immune Systems (AIS 2015)
July 17-18, 2015
Taormina, Italy

Visit our events page to see a complete list of events in the human immunology community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Fellow – Diffuse Large B-cell Lymphoma (University of Leeds)

Manufacturing Manager – Cell Therapy (Opexa Therapeutics)

Senior Research Officer – Immunology (Glenmark Pharmaceuticals S.A.)

Postdoctoral Fellowship – Human Immunology (University of Pennsylvania)

Postdoctoral Scientist – Immunology (University of Oxford)

Postdoctoral Position – Immunology (The Broad Institute of MIT and Harvard)

Faculty Position – Immunology (The Lowance Center for Human Immunology at Emory University)

Senior Process Development Engineer (Sangamo BioSciences, Inc.)

Director – Vector Production (Sangamo BioSciences, Inc.)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Human Immunology News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Human Immunology News: Archives | Events | Contact Us